A bioavailability study in the proposed patient population - With much more needed now

Critical Care Medicine

Volumn 31, Issue 5, 2003, Pages 1588-1589

  Freedman, Michael D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anti Xa; Enoxaparine; Intensive care; Low molecular weight heparins; Subcutaneous bioavailability; Surrogate markers; Thromboembolic prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EDITORIAL; HUMAN; INTENSIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; BIOLOGICAL AVAILABILITY; CRITICAL CARE; CRITICAL ILLNESS; DRUG MONITORING; ENOXAPARIN; HUMANS; INJECTIONS, SUBCUTANEOUS; THROMBOEMBOLISM;

EID: 0037566819     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000059726.55857.C5     Document Type: Editorial

References (13)

1. Attia J, Ray JG, Cook DJ, et al: Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161:1268-1279
2. Velmahos GC, Nigro J, Tatevossian R, et al: Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: Are current methods of DVT prophylaxis insufficient? J Am Coll Surg 1998; 187:529-533
3. Priglinger U, Delle Karth G, Geppert A, et al: Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003; 31:1405-1409
4. Mayer AJ, Dunser M, Jochberger S, et al: Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002; 105:201-204
5. Miric A, Lombardi P, Sculco TP: Deep vein thrombosis prophylaxis: A comprehensive approach for both total hip and total knee arthroplasty patient populations. Am J Orthop 2000; 29:269-274
6. Merli GJ: Prophylaxis for deep venous thrombosis and pulmonary embolism in the surgical patient. Clin Cornerstone 2000; 2:15-28
7. Devlin JW, Tyburski JG, Moed B: Implementation and evaluation of guidelines for the use of enoxaparin as deep vein thrombosis prophylaxis after major trauma. Pharmacotherapy 2001; 21:740-747
8. Antman EM, Cohen M, McCabe C, et al: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI IIB and ESSENCE. Eur Heart J 2002; 23:308-314
9. Massel D: Enoxaparin in acute coronary syndromes. Am Heart J 2002; 143:748-752
10. Freedman MD: Low molecular weight heparins: An emerging new class of glycosaminoglycan antithrombotics. J Clin Pharmacol 1991; 31:298-306
11. Haire WD: Pharmacologic Properties of LM-WHs, in Lovenox: Closed Consultants Meeting. Orlando, Aventis, 2000
12. Freedman MD, Leese P, Prasad R, et al: An evaluation of the biological response to Fraxiparine, (a low molecular weight heparin) in the healthy individual. J Clin Pharm 1990; 30(8):720-727
13. Dorffler-Melly J, de Jonge E, Pont AC, et al: Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002:359:849-850